Baker Bros. Advisors LP Fate Therapeutics Inc Transaction History
Baker Bros. Advisors LP
- $8.39 Billion
- Q1 2025
A detailed history of Baker Bros. Advisors LP transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Baker Bros. Advisors LP holds 3,258,402 shares of FATE stock, worth $4.04 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
3,258,402
Previous 3,258,402
-0.0%
Holding current value
$4.04 Million
Previous $5.38 Million
52.12%
% of portfolio
0.03%
Previous 0.06%
Shares
5 transactions
Others Institutions Holding FATE
# of Institutions
144Shares Held
97MCall Options Held
56.7KPut Options Held
5.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$16 Million1.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$12.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$12.5 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY7.79MShares$9.67 Million0.04% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.29MShares$5.32 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $120M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...